QL1701 (a proposed trastuzumab biosimilar) versus reference trastuzumab plus docetaxel as first-line therapy for HER2-positive metastatic breast cancer: a multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial
| Autor: | Zhang, Q.-Y., Cai, R.-G., Song, G.-H., Li, C.-J., Zhang, B.-H., Kang, X.-Y., Li, H.-P., Xu, B.-H. |
|---|---|
| Zdroj: | In ESMO Open September 2024 9(9) |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|